Strongest Antitussive Medication

Hierarchy of Antitussive Strength

Morphine is the strongest antitussive available, reserved for refractory cough unresponsive to other opioid derivatives, with a starting dose of 5 mg single-dose trial, and if effective, use 5-10 mg slow-release morphine twice daily 1, 2
Hydrocodone and dihydrocodeine are the most widely used and effective opioids for routine cough suppression, with hydrocodone dosed at 5 mg twice daily, and dihydrocodeine at 10 mg three times daily 1, 2, 3, 4
Dextromethorphan is the strongest non-opioid option, with maximum cough reflex suppression occurring at 60 mg, and a dose range of 10-15 mg three to four times daily, up to maximum 120 mg/day 1, 2, 5, 6

For severe, refractory cough requiring maximum suppression, start with hydrocodone 5 mg twice daily or dihydrocodeine 10 mg three times daily, and titrate hydrocodone up to 30 mg/day if needed 1, 2, 4
If inadequate response to first-line opioids, escalate to morphine 5 mg trial dose, and if effective, use 5-10 mg slow-release twice daily 1, 2
For patients where opioids are contraindicated or refused, use dextromethorphan 60 mg for maximum effect, or consider levodropropizine 75 mg three times daily if available 1, 2, 4, 5, 6

Availability of antitussive medications varies by country, and choice may be dictated by local formulary rather than pharmacologic superiority 1, 2
Patient's prior opioid exposure dictates initial starting dose, with opioid-naive patients requiring lower doses 1, 2
Codeine has an inferior benefit-to-risk ratio and should be avoided as first-line, despite its historical status as the "gold standard" 1, 2, 5, 6

Hydrocodone and dihydrocodeine demonstrate 40-60% suppression of cough counts in chronic bronchitis/COPD patients, with a comparable efficacy to codeine 7, 8, 9
Dextromethorphan achieves 40-60% cough suppression in chronic bronchitis/COPD, similar to codeine, but shows limited efficacy in upper respiratory infection-related cough (<20% suppression) 7, 8, 9, 10
Codeine demonstrates 40-60% suppression in chronic bronchitis, but its efficacy is inconsistent in upper respiratory infection-related cough 7, 8, 9, 10
Opioids, such as hydrocodone and dihydrocodeine, show strong efficacy in chronic bronchitis/COPD, but have inconsistent results in upper respiratory infections 7, 8, 10
The central cough mechanism differs between disease states, creating differential drug responses, with opioids being more effective in chronic bronchitis/COPD than in upper respiratory infections 7, 10

The American Thoracic Society acknowledges that the central cough mechanism differs between disease states, creating differential drug responses, with opioids being more effective in chronic bronchitis/COPD than in upper respiratory infections 7, 10

Dextromethorphan is the preferred antitussive agent over codeine for patients with brain metastasis at risk for repeat brain bleed, due to its superior efficacy and significantly better safety profile, particularly its lack of sedation and respiratory depression that could mask neurological deterioration 11, 12
The American Thoracic Society recommends dextromethorphan as a first-line treatment for cough suppression in high-risk patients, due to its effectiveness in controlling cough and its favorable side effect profile 11, 12

Dextromethorphan has been demonstrated to be more effective than codeine in controlling cough, including specifically in patients with lung cancer, with a significantly greater reduction in cough intensity (p < 0.0008) and a higher patient preference (p < 0.001) 11, 12
Both dextromethorphan and codeine achieve 40-60% suppression of cough counts in chronic bronchitis/COPD patients, according to the European Respiratory Society guidelines 13

Levodropropizine, a non-opioid alternative, showed significantly lower somnolence rates (8%) compared to dihydrocodeine (22%), highlighting the problematic sedation profile of opioid-based cough suppressants, as noted by the American Academy of Sleep Medicine 11, 12
Opioids like codeine carry risks of respiratory depression and hypoventilation that require careful monitoring, according to the Centers for Disease Control and Prevention 11, 12
Avoiding sedation is paramount in a patient with brain metastasis at risk for repeat hemorrhage, as sedation could mask critical neurological changes indicating acute bleeding, as recommended by the American Heart Association 11, 12